PPARG and Familial prostate cancer: Another clinical trial also tested a combined therapy with PPARγ agonist (rosiglitazone/pioglitazone), fenofibrate, and calcitriol in castration-resistant prostate cancer, but was terminated early due to low accrual (EUCTR 2006-001398-44).